Genome Editing: A New Approach to Human Therapeutics

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 163-190

  Porteus, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CRISPR Cas9; Gene targeting; Genome editing; Homologous recombination; Nonhomologous end joining; Stem cell; TAL effector nuclease; Zinc finger nuclease

Indexed keywords

CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; EXTRACHROMOSOMAL DNA; LENTIVIRUS VECTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESTRICTION ENDONUCLEASE; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; ZINC FINGER NUCLEASE; ENDONUCLEASE;

ARTICLE; BIOINFORMATICS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME INVERSION; CLONOGENESIS; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; DNA END JOINING REPAIR; DNA MODIFICATION; DOUBLE STRANDED DNA BREAK; FRAMESHIFT MUTATION; GENE DELETION; GENE INACTIVATION; GENE TARGETING; GENETIC ENGINEERING; GENOME; GERM LINE; HOMOLOGOUS RECOMBINATION; HUMAN; INDEL MUTATION; MUTAGENESIS; NEXT GENERATION SEQUENCING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; RNA EDITING; SINGLE NUCLEOTIDE POLYMORPHISM; TARGET CELL; TRANSGENE; ANIMAL; GENETICS; METABOLISM;

ANIMALS; DNA BREAKS, DOUBLE-STRANDED; ENDONUCLEASES; GENOME; HUMANS;

EID: 84954140058     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124454     Document Type: Article

References (200)

1. Carroll D. 2014. Genome engineering with targetable nucleases. Annu. Rev. Biochem. 83:409-39
2. Russell DW, Hirata RK. 1998. Human gene targeting by viral vectors. Nat. Genet. 18:325-30
3. Barzel A, Paulk NK, Shi Y, Huang Y, Chu K, et al. 2015. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517:360-64
4. Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW. 1983. The double-strand-break repair model for recombination. Cell 33:25-35
5. Orr-Weaver TL, Szostak JW, Rothstein RJ. 1983. Genetic applications of yeast transformation with linear and gapped plasmids. Methods Enzymol. 101:228-45
6. Doetschman T, Gregg RG, Maeda N, Hooper ML, Melton DW, et al. 1987. Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 330:576-78
7. Doetschman T, Maeda N, Smithies O. 1988. Targeted mutation of the Hprt gene in mouse embryonic stem cells. PNAS 85:8583-87
8. Thomas KR, Capecchi MR. 1986. Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene. Nature 324:34-38
9. Thomas KR,CapecchiMR. 1987. Site-directedmutagenesis by gene targeting inmouse embryo-derived stem cells. Cell 51:503-12
10. Mansour SL, Thomas KR, Capecchi MR. 1988. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes. Nature 336:348-52
11. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. 1985. Insertion of DNA sequences into the human chromosomal globin locus by homologous recombination. Nature 317:230-34
12. Rouet P, Smih F, Jasin M. 1994. Introduction of double-strand breaks into the genome of mouse cells by expression of rare-cutting endonuclease. Mol. Cell. Biol. 14:8096-106
13. Rouet P, Smih F, Jasin M. 1994. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. PNAS 91:6064-68
14. Smih F, Rouet P, Romanienko PJ, Jasin M. 1995. Double-strand breaks at the target locus stimulate gene targeting in embryonic stem cells. Nucleic Acids Res. 23:5012-19
15. Sargent RG, Brenneman MA, Wilson JH. 1997. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol. Cell. Biol. 17:267-77
16. Taghian DG, Nickoloff JA. 1997. Chromosomal double-strand breaks induce gene conversion at high frequency in mammalian cells. Mol. Cell. Biol. 17:6386-93
17. Choulika A, Perrin A, Dujon B, Nicolas J-F. 1995. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol. Cell. Biol. 15:1968-73
18. Porteus MH, Baltimore D. 2003. Chimeric nucleases stimulate gene targeting in human cells. Science 300:763
19. RudinN,Haber JE. 1988. Efficient repair of HO-induced chromosomal breaks in Saccharomyces cerevisiae by recombination between flanking homologous sequences. Mol. Cell. Biol. 8:3918-28
20. JasinM, Berg P. 1988. Homologous integration in mammalian cells without target gene selection. Genes Dev. 2:1353-63
21. Kim YG, Chandrasegaran S. 1994. Chimeric restriction endonuclease. PNAS 91:883-87
22. Kim YG, Cha J, Chandrasegaran S. 1996. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. PNAS 93:1156-60
23. Smith J, Berg JM, Chandrasegaran S. 1999. A detailed study of the substrate specificity of a chimeric restriction enzyme. Nucleic Acids Res. 27:674-81
24. Smith J, Bibikova M, Whitby FG, Reddy AR, Chandrasegaran S, Carroll D. 2000. Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res. 28:3361-69
25. Bibikova M, Carroll D, Segal DJ, Trautman JK, Smith J, et al. 2001. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol. Cell. Biol. 21:289-97
26. Bibikova M, Golic M, Golic KG, Carroll D. 2002. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161:1169-75
27. Bibikova M, Beumer K, Trautman JK, Carroll D. 2003. Enhancing gene targeting with designed zinc finger nucleases. Science 300:764
28. PorteusMH. 2006. Mammalian gene targeting with designed zinc finger nucleases. Mol. Ther. 13:438-46
29. Porteus MH, Carroll D. 2005. Gene targeting using zinc finger nucleases. Nat. Biotechnol. 23:967-73
30. Urnov FD, Miller JC, Lee YL, Beausejour CM,Rock JM, et al. 2005. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435:646-51
31. Kanaar R, Hoeijmakers JH, van Gent DC. 1998. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol. 8:483-89
32. Paques F, Haber JE. 1999. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 63:349-404
33. Khanna KK, Jackson SP. 2001. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27:247-54
34. West SC. 2003. Molecular views of recombination proteins and their control. Nat. Rev. Mol. Cell Biol. 4:435-45
35. Porteus M. 2011. Seeing the light: integrating genome engineering with double-strand break repair. Nat. Methods 8:628-30
36. Guirouilh-Barbat J, Huck S, Bertrand P, Pirzio L, Desmaze C, et al. 2004. Impact of the KU80 pathway on NHEJ-induced genome rearrangements in mammalian cells. Mol. Cell 14:611-23
37. CertoMT, Gwiazda KS, Kuhar R, Sather B, Curinga G, et al. 2012. Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. Nat. Methods 9:973-75
38. Richardson C, Jasin M. 2000. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 405:697-700
39. Lee HJ, Kim E, Kim JS. 2010. Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res. 20:81-89
40. Hendel A, Kildebeck EJ, Fine EJ,Clark JT, PunjyaN, et al. 2014. Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. Cell Rep. 7:293-305
41. Voit RA, McMahon MA, Sawyer SL, Porteus MH. 2013. Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. Mol. Ther. 21:786-95
42. Moehle EA, Rock JM, Lee YL, Jouvenot Y, DeKelver RC, et al. 2007. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. PNAS 104:3055-60
43. Potts PR, Porteus MH, Yu H. 2006. Human SMC5/6 complex promotes sister chromatid homologous recombination by recruiting the SMC1/3 cohesin complex to double-strand breaks. EMBOJ. 25:3377-88
44. Yu C, Liu Y, Ma T, Liu K, Xu S, et al. 2015. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16:142-47
45. Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL. 2015. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33:538-42
46. CertoMT, Ryu BY, Annis JE, Garibov M, Jarjour J, et al. 2011. Tracking genome engineering outcome at individual DNA breakpoints. Nat. Methods 8:671-76
47. Chu VT, Weber T,Wefers B,Wurst W, Sander S, et al. 2015. Increasing the efficiency of homologydirected repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33:543-48
48. LimDS, Hasty P. 1996. Amutation inmouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol. Cell. Biol. 16:7133-43
49. Fattah FJ, Lichter NF, Fattah KR, Oh S, Hendrickson EA. 2008. Ku70, an essential gene, modulates the frequency of rAAV-mediated gene targeting in human somatic cells. PNAS 105:8703-8
50. SilvaG, Poirot L,Galetto R, Smith J,Montoya G, et al. 2011. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr. Gene Ther. 11:11-27
51. Jurica MS, Stoddard BL. 1999. Homing endonucleases: structure, function and evolution. Cell. Mol. Life Sci. 55:1304-26
52. Chevalier BS, Kortemme T, Chadsey MS, Baker D, Monnat RJ, Stoddard BL. 2002. Design, activity, and structure of a highly specific artificial endonuclease. Mol. Cell 10:895-905
53. Volná P, Jarjour J, Baxter S, Roffler SR, Monnat RJ Jr, et al. 2007. Flow cytometric analysis of DNA binding and cleavage by cell surface-displayed homing endonucleases. Nucleic Acids Res. 35:2748-58
54. Jarjour J, West-Foyle H, Certo MT, Hubert CG, Doyle L, et al. 2009. High-resolution profiling of homing endonuclease binding and catalytic specificity using yeast surface display. Nucleic Acids Res. 37:6871-80
55. Thyme SB, Jarjour J, Takeuchi R, Havranek JJ, Ashworth J, et al. 2009. Exploitation of binding energy for catalysis and design. Nature 461:1300-4
56. Epinat JC, Arnould S, Chames P, Rochaix P, Desfontaines D, et al. 2003. A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells. Nucleic Acids Res. 31:2952-62
57. Segal DJ, Barbas CF III. 2001. Custom DNA-binding proteins come of age: polydactyl zinc-finger proteins. Curr. Opin. Biotechnol. 12:632-37
58. Beerli RR, Barbas CF III. 2002. Engineering polydactyl zinc-finger transcription factors. Nat. Biotechnol. 20:135-41
59. Liu Q, Xia Z, Zhong X, Case CC. 2002. Validated zinc finger protein designs for all 16 GNN DNA triplet targets. J. Biol. Chem. 277:3850-56
60. Greisman HA, Pabo CO. 1997. A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. Science 275:657-61
61. Rebar EJ, Pabo CO. 1994. Zinc finger phage: Affinity selection of fingers with new DNA-binding specificities. Science 263:671-73
62. Pruett-Miller SM, Connelly JP, Maeder ML, Joung JK, Porteus MH. 2008. Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol. Ther. 16:707-17
63. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, et al. 2008. Rapid "opensource" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol. Cell 31:294-301
64. Meng X, BrodskyMH,Wolfe SA. 2005. Abacterial one-hybrid system for determining theDNA-binding specificity of transcription factors. Nat. Biotechnol. 23:988-94
65. Persikov AV,Wetzel JL, Rowland EF, Oakes BL, Xu DJ, et al. 2015. A systematic survey of the Cys2His2 zinc finger DNA-binding landscape. Nucleic Acids Res. 43:1965-84
66. Persikov AV, Rowland EF, Oakes BL, Singh M, Noyes MB. 2014. Deep sequencing of large library selections allows computational discovery of diverse sets of zinc fingers that bind common targets. Nucleic Acids Res. 42:1497-508
67. Isalan M, Klug A, Choo Y. 2001. A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. Nat. Biotechnol. 19:656-60
68. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. 2008. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26:808-16
69. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, et al. 2010. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186:757-61
70. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, et al. 2011. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39:e82
71. Bogdanove AJ, Voytas DF. 2011. TAL effectors: customizable proteins for DNA targeting. Science 333:1843-46
72. Miller JC, Tan S, Qiao G, Barlow KA,Wang J, et al. 2011. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29:143-48
73. Joung JK, Sander JD. 2013. TALENs: A widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14:49-55
74. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, et al. 2009. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326:1509-12
75. Moscou MJ, Bogdanove AJ. 2009. A simple cipher governs DNA recognition by TAL effectors. Science 326:1501
76. Miller JC, ZhangL,Xia DF,Campo JJ, Ankoudinova IV, et al. 2015. Improved specificity ofTALE-based genome editing using an expanded RVD repertoire. Nat. Methods 12:465-71
77. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. 2012. FLASH assembly of TALENs for high-throughput genome editing. Nat. Biotechnol. 30:460-65
78. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816-21
79. Doudna JA, Charpentier E. 2014. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346:1258096
80. Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, et al. 2011. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471:602-7
81. Charpentier E. 2015. CRISPR-Cas9: how research on a bacterial RNA-guided mechanism opened new perspectives in biotechnology and biomedicine. EMBO Mol. Med. 7:363-65
82. Mali P, Yang L, Esvelt KM, Aach J, Guell M, et al. 2013. RNA-guided human genome engineering via Cas9. Science 339:823-26
83. Cong L, Ran FA, CoxD,Lin S, Barretto R, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819-23
84. Ran FA, Cong L, YanWX, Scott DA, Gootenberg JS, et al. 2015. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186-91
85. Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM. 2013. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat. Methods 10:1116-21
86. Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, et al. 2015. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523:481-85
87. Ramirez CL, Certo MT, Mussolino C, Goodwin MJ, Cradick TJ, et al. 2012. Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Res. 40:5560-68
88. Davis L,Maizels N. 2014. Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair. PNAS 111:E924-32
89. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, et al. 2013. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31:833-38
90. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, et al. 2013. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154:1380-89
91. Boissel S, Jarjour J, Astrakhan A, Adey A, Gouble A, et al. 2014. MegaTALs: A rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res. 42:2591-601
92. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, et al. 2014. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 32:569-76
93. Guilinger JP, Thompson DB, Liu DR. 2014. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 32:577-82
94. Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, et al. 2015. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33:985-89
95. Genovese P, Schiroli G, Escobar G, Di Tomaso T, Firrito C, et al. 2014. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510:235-40
96. Mock U, Machowicz R, Hauber I, Horn S, Abramowski P, et al. 2015. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res. 43:5560-71
97. Doyon Y, Choi VM, Xia DF, Vo TD, Gregory PD, Holmes MC. 2010. Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat. Methods 7:459-60
98. Voit RA, Hendel A, Pruett-Miller SM, Porteus MH. 2014. Nuclease-mediated gene editing by homologous recombination of the human globin locus. Nucleic Acids Res. 42:1365-78
99. SargentRG, Suzuki S, Gruenert DC. 2014. Nuclease-mediated double-strand break (DSB) enhancement of small fragment homologous recombination (SFHR) gene modification in human-induced pluripotent stem cells (hiPSCs). Methods Mol. Biol. 1114:279-90
100. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, et al. 2007. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 25:1298-306
101. Porteus MH, Cathomen T, Weitzman MD, Baltimore D. 2003. Efficient gene targeting mediated by adeno-associated virus and DNA double-strand breaks. Mol. Cell. Biol. 23:3558-65
102. Miller DG, Petek LM, Russell DW. 2003. Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks. Mol. Cell. Biol. 23:3550-57
103. Ellis BL, Hirsch ML, Porter SN, Samulski RJ, Porteus MH. 2013. Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administrationapproved drugs. Gene Ther. 20:35-42
104. HirschML,Green L, PorteusMH, Samulski RJ. 2010. Self-complementaryAAVmediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther. 17:1175-80
105. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, et al. 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32:551-53
106. Chen F, Pruett-Miller SM, Huang Y, Gjoka M, Duda K, et al. 2011. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat. Methods 8:753-55
107. Papaioannou I, Simons JP, Owen JS. 2012. Oligonucleotide-directed gene-editing technology: mechanisms and future prospects. Expert Opin. Biol. Ther. 12:329-42
108. Maggio I, Gonçalves MA. 2015. Genome editing at the crossroads of delivery, specificity, and fidelity. Trends Biotechnol. 33:280-91
109. Holt N, Wang J, Kim K, FriedmanG,Wang X, et al. 2010. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28:839-47
110. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, et al. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370:901-10
111. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, et al. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360:692-98
112. Cradick TJ, Fine EJ, Antico CJ, Bao G. 2013. CRISPR/Cas9 systems targeting globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41:9584-92
113. Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, et al. 2014. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15:643-52
114. Mussolino C, Morbitzer R, Lütge F, Dannemann N, Lahaye T, Cathomen T. 2011. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. 39:9283-93
115. Berdien B, Mock U, Atanackovic D, Fehse B. 2014. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 21:539-48
116. Provasi E, Genovese P, Lombardo A,Magnani Z, Liu PQ, et al. 2012. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18:807-15
117. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, et al. 2012. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119:5697-705
118. Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, et al. 2014. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 115:488-92
119. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37:161-65
120. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264-72
121. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, et al. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79:514-23
122. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. 2010. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol. Ther. 18:947-54
123. Schiffer JT, Aubert M, WeberND, Mintzer E, Stone D, Jerome KR. 2012. Targeted DNA mutagenesis for the cure of chronic viral infections. J. Virol. 86:8920-36
124. Saayman S, Ali SA, Morris KV, Weinberg MS. 2015. The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin. Biol. Ther. 15:819-30
125. Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, et al. 2015. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat. Commun. 6:6413
126. Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, et al. 2013. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol. Ther. 21:1718-26
127. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. 2015. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 6:6244
128. Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, et al. 2015. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol. Ther. 23:523-32
129. Li Y, Polak U, Bhalla AD, Rozwadowska N, Butler JS, et al. 2015. Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich's ataxia. Mol. Ther. 23:1055-65
130. Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, et al. 2013. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 342:253-57
131. Lee HJ, Kweon J, Kim E, Kim S, Kim JS. 2012. Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases. Genome Res. 22:539-48
132. Park CY, Kim J, Kweon J, Son JS, Lee JS, et al. 2014. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. PNAS 111:9253-58
133. Johnston JJ, Lewis KL, Ng D, Singh LN, Wynter J, et al. 2015. Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations. Am. J. Hum. Genet. 96:913-25
134. Sulem P, Helgason H, Oddson A, Stefansson H, Gudjonsson SA, et al. 2015. Identification of a large set of rare complete human knockouts. Nat. Genet. 47:448-52
135. Kildebeck E, Checketts J, Porteus M. 2012. Gene therapy for primary immunodeficiencies. Curr. Opin. Pediatr. 24:731-38
136. Gaziev J, Lucarelli G. 2010. Allogeneic cellular gene therapy for hemoglobinopathies. Hematol. /Oncol. Clin. North Am. 24:1145-63
137. Zou J, Mali P, Huang X, Dowey SN, Cheng L. 2011. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118:4599-608
138. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, et al. 2011. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29:1717-26
139. OsbornMJ, Gabriel R,Webber BR, DeFeo AP, McElroy AN, et al. 2015. Fanconi anemia gene editing by the CRISPR/Cas9 system. Hum. Gene Ther. 26:114-26
140. Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, et al. 2013. TALEN-based gene correction for epidermolysis bullosa. Mol. Ther. 21:1151-59
141. Flynn R,Grundmann A, Renz P, HaenselerW, James WS, et al. 2015. CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. Exp. Hematol. 43(10):838-48
142. Dupuy A, Valton J, Leduc S, Armier J, Galetto R, et al. 2013. Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALEN. PLOS ONE 8:e78678
143. Ma N, Liao B, Zhang H, Wang L, Shan Y, et al. 2013. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free thalassemia induced pluripotent stem cells. J. Biol. Chem. 288:34671-79
144. Popplewell L, Koo T, Leclerc X, Duclert A, Mamchaoui K, et al. 2013. Gene correction of a Duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. Hum. Gene Ther. 24:692-701
145. Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, et al. 2011. Genomic safe harbors permit high globin transgene expression in thalassemia induced pluripotent stem cells. Nat. Biotechnol. 29:73-78
146. DeKelver RC, Choi VM, Moehle EA, Paschon DE, Hockemeyer D, et al. 2010. Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res. 20:1133-42
147. Lombardo A, Cesana D, Genovese P, Di Stefano B, Provasi E, et al. 2011. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat. Methods 8:861-69
148. Sadelain M, Papapetrou EP, Bushman FD. 2012. Safe harbours for the integration of new DNA in the human genome. Nat. Rev. Cancer 12:51-58
149. Coluccio A, Miselli F, Lombardo A, Marconi A, Malagoli Tagliazucchi G, et al. 2013. Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. Mol. Ther. 21:1695-704
150. Chang CJ, Bouhassira EE. 2012. Zinc-finger nuclease-mediated correction of thalassemia in iPS cells. Blood 120:3906-14
151. Zou J, Sweeney CL, Chou BK, Choi U, Pan J, et al. 2011. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 117:5561-72
152. Merling RK, Sweeney CL, Chu J, Bodansky A, Choi U, et al. 2015. An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease. Mol. Ther. 23:147-57
153. Benabdallah BF, Allard E, Yao S, Friedman G, Gregory PD, et al. 2010. Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. Cytotherapy 12:394-99
154. Barker JC,Barker AD, Bills J, Huang J,Wight-CarterM, et al. 2014. Genome editing ofmouse fibroblasts by homologous recombination for sustained secretion of PDGF-B and augmentation of wound healing. Plast. Reconstr. Surg. 134:389e-401e
155. Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE, Kiem HP. 2010. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J. Clin. Investig. 120:2345-54
156. Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, et al. 2003. Safety of retroviral gene marking with a truncated NGF receptor. Nat. Med. 9:367-69
157. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365:1673-83
158. Zhou X, Dotti G, Krance RA,MartinezCA, Naik S, et al. 2015. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 125:4103-13
159. Vogler I, Newrzela S, Hartmann S, Schneider N, von Laer D, et al. 2010. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol. Ther. 18:1330-38
160. Wang X, ChangWC, Wong CW, Colcher D, Sherman M, et al. 2011. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118:1255-63
161. Anguela XM, Sharma R, Doyon Y, Miller JC, Li H, et al. 2013. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 122:3283-87
162. Li H, Haurigot V, Doyon Y, Li T, Wong SY, et al. 2011. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475:217-21
163. Cheng LT, Sun LT, Tada T. 2012. Genome editing in induced pluripotent stem cells. Genes Cells 17:431-38
164. Sebastiano V, Zhen HH, Haddad B, Bashkirova E, Melo SP, et al. 2014. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci. Transl. Med. 6:264ra163
165. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, et al. 2007. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920-23
166. Bousso P, Wahn V, Douagi I, Horneff G, Pannetier C, et al. 2000. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. PNAS 97:274-78
167. Weinstock DM, Richardson CA, Elliott B, Jasin M. 2006. Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair. 5:1065-74
168. Pierce AJ, Stark JM, Araujo FD, Moynahan ME, Berwick M, Jasin M. 2001. Double-strand breaks and tumorigenesis. Trends Cell Biol. 11:S52-59
169. Corrigan-Curay J,O'Reilly M, Kohn DB,Cannon PM, BaoG, et al. 2015. Genome editing technologies: defining a path to clinic. Mol. Ther. 23:796-806
170. Hendel A, Fine EJ, Bao G, Porteus MH. 2015. Quantifying on-and off-target genome editing. Trends Biotechnol. 33:132-40
171. Cradick TJ, Qiu P, Lee CM, Fine EJ, Bao G. 2014. COSMID: A web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol. Ther. Nucleic Acids 3:e214
172. Fine EJ, Cradick TJ, Zhao CL, Lin Y, Bao G. 2014. An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res. 42:e42
173. Pattanayak V, Guilinger JP, Liu DR. 2014. Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. Methods Enzymol. 546:47-78
174. Pattanayak V, Ramirez CL, Joung JK, Liu DR. 2011. Revealing off-target cleavage specificities of zincfinger nucleases by in vitro selection. Nat. Methods 8:765-70
175. Guilinger JP, Pattanayak V, Reyon D, Tsai SQ, Sander JD, et al. 2014. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat. Methods 11:429-35
176. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR. 2013. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31:839-43
177. Lin Y,Waldman AS. 2001. Capture of DNA sequences at double-strand breaks in mammalian chromosomes. Genetics 158:1665-74
178. Lin Y, Waldman AS. 2001. Promiscuous patching of broken chromosomes in mammalian cells with extrachromosomal DNA. Nucleic Acids Res. 29:3975-81
179. Miller DG, Petek LM, Russell DW. 2004. Adeno-associated virus vectors integrate at chromosome breakage sites. Nat. Genet. 36:767-73
180. Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P, et al. 2011. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 29:816-23
181. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, et al. 2014. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33:187-97
182. Chiarle R, Zhang Y, Frock RL,Lewis SM,Molinie B, et al. 2011. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 147:107-19
183. Frock RL, Hu J, Meyers RM, Ho YJ, Kii E, Alt FW. 2015. Genome-wide detection of DNA doublestranded breaks induced by engineered nucleases. Nat. Biotechnol. 33:179-86
184. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, et al. 2007. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 25:778-85
185. Pruett-Miller SM, Reading DW, Porter SN, Porteus MH. 2009. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLOS Genet. 5:e1000376
186. Doyon Y, Vo TD, Mendel MC, Greenberg SG, Wang J, et al. 2011. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat. Methods 8:74-79
187. Szczepek M, Brondani V, Buchel J, Serrano L, Segal DJ, Cathomen T. 2007. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 25:786-93
188. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, et al. 2014. Clinical interpretation and implications of whole-genome sequencing. JAMA 311:1035-45
189. Tomasetti C, Vogelstein B. 2015. Cancer risk: role of environment-response. Science 347:729-31
190. Tomasetti C, Vogelstein B. 2015. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347:78-81
191. MussolinoC, Alzubi J, Fine EJ,Morbitzer R, Cradick TJ, et al. 2014. TALENsfacilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res. 42:6762-73
192. Porter SN, Baker LC, Mittelman D, Porteus MH. 2014. Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo. Genome Biol. 15:R75
193. Li L, Krymskaya L, Wang J, Henley J, Rao A, et al. 2013. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol. Ther. 21:1259-69
194. Liang P, Xu Y, Zhang X, Ding C, Huang R, et al. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6:363-72
195. Reddy P, Ocampo A, Suzuki K, Luo J, Bacman SR, et al. 2015. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 161:459-69
196. Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J. 2015. Don't edit the human germ line. Nature 519:410-11
197. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, et al. 2015. A prudent path forward for genomic engineering and germline gene modification. Science 348:36-38
198. Porteus MH, Dann CT. 2015. Genome editing of the germline: broadening the discussion. Mol. Ther. 23:980-82
199. Miller HI. 2015. Germline gene therapy:We're ready. Science 348:1325
200. Fanslow DA, Wirt SE, Barker JC, Connelly JP, Porteus MH,Dann CT. 2014. Genome editing inmouse spermatogonial stem/progenitor cells using engineered nucleases. PLOS ONE 9:e112652